Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Komtebedde

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
JACC. Heart Failure|March 11, 2019
Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection FractionEmil Wolsk, David Kaye, Jan Komtebedde, et al.
European Journal of Heart Failure|February 27, 2023
Left atrial enlargement is associated with pulmonary vascular disease in heart failure with preserved ejection fractionEmma K Gard, Anna L Beale, Fernando Telles, et al.
JACC. Heart Failure|July 27, 2025
Expanded Definition of Worsening Heart Failure: Impact on Clinical Outcomes and Quality-of-Life AssessmentRichard S Chaudhary, Syed M D Hussain, Yong-Shi Wang, et al.
The American Journal of Cardiology|October 27, 2019
Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial)Thomas C Hanff, David M Kaye, Christopher S Hayward, et al.
Circulation. Heart Failure|June 23, 2016
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I)Ted Feldman, Jan Komtebedde, Daniel Burkhoff, et al.
JAMA Cardiology|April 17, 2024
Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical TrialRavi B Patel, Frank E Silvestry, Jan Komtebedde, et al.
JACC. Heart Failure|June 27, 2024
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF IIFinn Gustafsson, Mark C Petrie, Jan Komtebedde, et al.
European Journal of Heart Failure|November 21, 2023
Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trialSheldon E Litwin, Jan Komtebedde, Tim Seidler, et al.
JACC. Advances|September 2, 2025
Epicardial adipose tissue, functional status and invasive hemodynamics in heart failure with preserved ejection fractionYoran Crum, Dirk J van Veldhuisen, Sanjiv J Shah, et al.
American Heart Journal|September 5, 2024
Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trialsSheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
JACC. Heart Failure|March 11, 2019
Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection FractionEmil Wolsk, David Kaye, Jan Komtebedde, et al.
European Journal of Heart Failure|February 27, 2023
Left atrial enlargement is associated with pulmonary vascular disease in heart failure with preserved ejection fractionEmma K Gard, Anna L Beale, Fernando Telles, et al.
JACC. Heart Failure|July 27, 2025
Expanded Definition of Worsening Heart Failure: Impact on Clinical Outcomes and Quality-of-Life AssessmentRichard S Chaudhary, Syed M D Hussain, Yong-Shi Wang, et al.
The American Journal of Cardiology|October 27, 2019
Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial)Thomas C Hanff, David M Kaye, Christopher S Hayward, et al.
Circulation. Heart Failure|June 23, 2016
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I)Ted Feldman, Jan Komtebedde, Daniel Burkhoff, et al.
JAMA Cardiology|April 17, 2024
Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical TrialRavi B Patel, Frank E Silvestry, Jan Komtebedde, et al.
JACC. Heart Failure|June 27, 2024
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF IIFinn Gustafsson, Mark C Petrie, Jan Komtebedde, et al.
European Journal of Heart Failure|November 21, 2023
Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trialSheldon E Litwin, Jan Komtebedde, Tim Seidler, et al.
JACC. Advances|September 2, 2025
Epicardial adipose tissue, functional status and invasive hemodynamics in heart failure with preserved ejection fractionYoran Crum, Dirk J van Veldhuisen, Sanjiv J Shah, et al.
American Heart Journal|September 5, 2024
Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trialsSheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
Pageof 4